Feature | February 10, 2014

Inflammation Testing May Predict Cardiac Risk in Corporate Wellness Programs

February 10, 2014 — Traditional fingerstick screening for glucose and lipids is proving inadequate when identifying near-term cardiovascular risk in employed populations, according to Jake Orville, CEO of Cleveland HeartLab (CHL). This position is supported by data from the American Heart Association. AHA reported 50 percent of all heart attacks and strokes occur in individuals with normal cholesterol and — for approximately 30 percent of patients with cardiovascular disease — their first sign of disease is death.
 
Orville is scheduled to present "The Role of Inflammation Testing in Corporate Wellness Programs" at the 2014 Health & Wellness Congress, Feb. 27-28. The conference, held at the Monte Carlo Resort and Casino in Las Vegas, will bring together leading corporate wellness experts to discuss emerging trends and strategies that promote well-being at the worksite.
 
"Inflammation testing provides reassurance on another important level," Orville said. "In addition to detecting employees with possible hidden risk, we are also able to provide positive feedback for those employees who are already leading healthy lifestyles. Knowing that their health habits are decreasing the inflammation in their blood vessels and their risk of an event can be a powerful incentive for people to stick with positive lifestyle changes."
 
Cleveland HeartLab is a provider of onsite testing for corporate wellness programs. A clinical laboratory and cardiovascular disease management provider, CHL offers a multi-marker approach — adding inflammation-specific blood tests to the traditional screening panel — to identify employees may go undetected. CHL's inflammatory biomarkers deliver insight into cardiovascular disease risk such as "vulnerable plaque" that may rupture into the vessel and block blood flow, leading to heart attack or stroke.
 
Orville will present both the science of inflammation testing and the results of corporate wellness programs that have adopted inflammation testing for risk stratification and targeted intervention. With new mandates from the Affordable Care Act for companies to provide screening programs to employees, obtaining the greatest efficacy as well as return on investment becomes paramount.
 
For more information: www.clevelandheartlab.com

Related Content

Image courtesy of Boston Scientific

Feature | Business| February 10, 2016 | Dave Fornell
After five years of almost constant lobbying efforts and numerous attempts by the U.S.
CeloNova, COBRA REDUCE trial, first patient enrolled, Cobra PzF coronary stent
News | Stents| February 10, 2016
CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA REDUCE trial. The...
Mount Sinai Heart, TANSNIP-PESA study, worksite lifestyle intervention, cardiovascular risk
News | Cardiac Diagnostics| February 09, 2016
Mount Sinai Heart is undertaking a three-year study to determine whether a workplace-based lifestyle intervention,...
ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
News | Cardiac Diagnostics| February 08, 2016
February 8, 2016 — A parent’s incarceration has immediate, devastating effects on a family.
caffeine consumption, extra heartbeats, UCSF study, UC San Francisco, Journal of the American Heart Association
News | EP Lab| February 04, 2016
Contrary to current clinical belief, regular caffeine consumption does not lead to extra heartbeats, which, while...
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
Abbott, Alere, acquisition, point of care diagnostics
News | Point of Care Testing| February 03, 2016
Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms of the agreement,...
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Overlay Init